Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
30 April 2019 |
Main ID: |
EUCTR2014-003480-37-GB |
Date of registration:
|
20/10/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease
|
Scientific title:
|
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease |
Date of first enrolment:
|
10/03/2015 |
Target sample size:
|
23 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003480-37 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: External Control (Historical Control) Number of treatment arms in the trial: 1
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Germany
|
Italy
|
United Kingdom
|
United States
| | | | |
Contacts
|
Name:
|
Clinical Trials Information
|
Address:
|
105 Digital Drive
94949
Novato
United States |
Telephone:
|
|
Email:
|
clinicaltrials@bmrn.com |
Affiliation:
|
BioMarin Pharmaceutical Inc. |
|
Name:
|
Clinical Trials Information
|
Address:
|
105 Digital Drive
94949
Novato
United States |
Telephone:
|
|
Email:
|
clinicaltrials@bmrn.com |
Affiliation:
|
BioMarin Pharmaceutical Inc. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: •Must have completed 48 weeks in Study 190-201 •Is willing and able to provide written, signed informed consent. Or, in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorized representative, after the nature of the study has been explained, and prior to performance of research-related procedures •If sexually active, must be willing to use an acceptable method of contraception while participating in the study •If female, of childbearing potential, must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests done during the study
Are the trial subjects under 18? yes Number of subjects for this age range: 23 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: •Has had a loss of 3 or more points in the combined motor and language components of the Hamburg CLN2 rating scale between Baseline of Study 190-201 and the Study Completion visit in Study 190-201 and would not benefit from enrolling in the study in the Investigator’s discretion •Has a score of 0 points on the combined motor and language components of the Hamburg CLN2 rating scale •Is pregnant or breastfeeding, at Baseline, or planning to become pregnant (self or partner) at any time during the study •Has used any investigational product (other than BMN 190 in 190-201), or investigational medical device, within 30 days prior to Baseline; or is required to use any investigational agent prior to completion of all scheduled study assessments •Has a concurrent disease or condition that would interfere with study participation, or pose a safety risk, as determined by the Investigator •Has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Late-Infantile Neuronal Ceroid Lipofuscinosis type 2 (CLN2).
MedDRA version: 20.1
Level: LLT
Classification code 10052074
Term: Neuronal ceroid lipofuscinosis NOS
System Organ Class: 100000004850
|
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|
Intervention(s)
|
Trade Name: Brineura Product Code: BMN 190 Pharmaceutical Form: Solution for infusion INN or Proposed INN: cerliponase alfa CAS Number: 151662-36-1 Current Sponsor code: BMN 190 Other descriptive name: RECOMBINANT HUMAN TRIPEPTIDYL PEPTIDASE-1 (RHTPP1) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-
|
Primary Outcome(s)
|
Primary end point(s): The primary points of the study include the following: •to evaluate the long-term safety of BMN 190 administration at 300 mg qow in patients with CLN2 •to assess change in motor and language subscales of the CLN2 disease rating scale in patients with CLN2 receiving BMN 190 at 300 mg qow
|
Timepoint(s) of evaluation of this end point: Patients will complete safety assessments including CSF surveillance labs and a brief physical examination every 2 weeks. Clinical laboratory tests and immunogenicity tests will be performed every 12 weeks. Efficacy per the disease scales will be assessed every 8 weeks.
|
Secondary Objective: The secondary objectives of the study include the following: •to assess changes in quantitative assessment of MRI •to assess change in CLN2 disease scale total score •to evaluate quality of life (QOL) with long-term BMN 190 administration
|
Main Objective: The primary objectives of this study include the following: •to evaluate the long-term safety of BMN 190 administration at 300 mg qow in patients with CLN2 •to assess change in motor and language subscales of the CLN2 disease rating scale in patients with CLN2 receiving BMN 190 at 300 mg qow
|
Secondary Outcome(s)
|
Secondary end point(s): Secondary endpoints of the study include the following: •to assess changes in quantitative assessment of MRI •to assess change in CLN2 disease scale total score •to evaluate quality of life (QOL) with long-term BMN 190 administration
|
Timepoint(s) of evaluation of this end point: MRI and quality of life measures will be collected every 24 weeks. Total score on the disease scales will be assessed every 8 weeks.
|
Source(s) of Monetary Support
|
BioMarin Pharmaceutical Inc.
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|